A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

NCT01844180 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Irritable Bowel Syndrome (IBS)

Interventions

DRUG: ONO-2952
DRUG: ONO-2952 Matching Placebo

Sponsor

Ono Pharma USA Inc